Onasemnogene Abeparvovec (Zolgensma): Market Report

Onasemnogene Abeparvovec (Zolgensma): Market Analysis, Patent Landscape, And Competitive Outlook, 2025 - 2033

Published: Nov, 2025
Report ID: GVR-MT-100517
Format: PDF/Excel databook

No. of Pages/Datapoints: 120
Report Coverage: 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
  1.2. Segment Definitions
  1.3. Estimates and Forecast Timeline
  1.4. Research Methodology
  1.5. Information Procurement
1.5.1. Purchased Database
  1.5.2. GVR’s Internal Database
  1.5.3. Secondary Sources
  1.5.4. Primary Research
  1.6. Information Analysis
  1.6.1. Data Analysis Models
  1.7. Market Formulation & Data Visualization
  1.8. Model Details
  1.8.1. Commodity Flow Analysis
  1.9. List of Secondary Sources
  1.10. Objectives
Chapter 2. Executive Summary
  2.1. Market Snapshot
  2.2. Segment Snapshot
  2.3. Competitive Landscape Snapshot
Chapter 3. Onasemnogene abeparvovec (Zolgensma) Variables, Trends, & Scope
  3.1. Market Lineage Outlook
  3.2. Market Dynamics
  3.2.1. Market Driver Analysis
  3.2.2. Market Restraint Analysis
  3.3. Business Environment Analysis
  3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
  3.3.1.2. Buyer Power
  3.3.1.3. Substitution Threat
  3.3.1.4. Threat of New Entrants
  3.3.1.5. Competitive Rivalry
  3.3.2. PESTLE Analysis
  3.3.3. Pipeline Analysis
  3.3.4. Pricing Analysis
Chapter 4. Onasemnogene abeparvovec (Zolgensma): Indication Business Analysis
  4.1. Indication Market Share, 2024 & 2033
  4.2. Indication Segment Dashboard
  4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  4.4. Spinal Muscular Atrophy Type 1
  4.4.1. Spinal Muscular Atrophy Type 1 Market, 2021 - 2033 (USD Million)
  4.5. Pre-Symptomatic SMA with Bi-Allelic SMN1 Mutations
  4.5.1. Pre-Symptomatic SMA with Bi-Allelic SMN1 Mutations Market, 2021 - 2033 (USD Million)
  4.6. SMA Patients with Up to Three SMN2 Copies
  4.6.1. SMA Patients with Up to Three SMN2 Copies Market, 2021 - 2033 (USD Million)
Chapter 5. Onasemnogene abeparvovec (Zolgensma): Regional Estimates & Trend Analysis
  5.1. Regional Market Share Analysis, 2024 & 2033
  5.2. Regional Market Dashboard
  5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  5.4. North America
  5.5. Europe
  5.6. Asia Pacific
  5.7. Latin America
  5.8. Middle East and Africa
Chapter 6. Competitive Landscape
  6.1. Company Profile
  6.1.1. Novartis
  6.1.1.1. Overview
  6.1.1.2. Financial Performance
  6.1.1.3. Strategic Mapping
  6.2. Concurrent Competitive Landscape
  6.2.1. Biogen
  6.2.1.1. Overview
  6.2.1.2. Financial Performance
  6.2.1.3. Product Benchmarking
  6.2.1.4. Strategic Mapping
  6.2.2. Roche / Genentech
  6.2.2.1. Overview
  6.2.2.2. Financial Performance
  6.2.2.3. Product Benchmarking
  6.2.2.4. Strategic Mapping
  6.2.3. PTC Therapeutics
  6.2.3.1. Overview
  6.2.3.2. Financial Performance
  6.2.3.3. Product Benchmarking
  6.2.3.4. Strategic Mapping

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Onasemnogene abeparvovec (Zolgensma), by region, 2021 - 2033 (USD Million)
Table 4. North America Onasemnogene abeparvovec (Zolgensma), by Indication, 2021 - 2033 (USD Million)
Table 5. Europe Onasemnogene abeparvovec (Zolgensma), by Indication, 2021 - 2033 (USD Million)
Table 6. Asia Pacific Onasemnogene abeparvovec (Zolgensma), by Indication, 2021 - 2033 (USD Million)
Table 7. Latin America Onasemnogene abeparvovec (Zolgensma), by Indication, 2021 - 2033 (USD Million)
Table 8. Middle East & Africa Onasemnogene abeparvovec (Zolgensma), by Indication, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Onasemnogene abeparvovec (Zolgensma) segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market Healthcare Setting & validation
Fig. 8 Market snapshot
Fig. 9 Mechanism of Action outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Onasemnogene abeparvovec (Zolgensma) dynamics
Fig. 12 Onasemnogene abeparvovec (Zolgensma): Porter’s five forces analysis
Fig. 13 Onasemnogene abeparvovec (Zolgensma): PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Spinal Muscular Atrophy Type 1 market, 2021 - 2033 (USD Million)
Fig. 16 Pre-Symptomatic SMA with Bi-Allelic SMN1 Mutations market, 2021 - 2033 (USD Million)
Fig. 17 SMA Patients with Up to Three SMN2 Copies market, 2021 - 2033 (USD Million)
Fig. 18 Regional marketplace: Key takeaways
Fig. 19 North America Onasemnogene abeparvovec (Zolgensma), 2021 - 2033 (USD Million)
Fig. 20 Europe Onasemnogene abeparvovec (Zolgensma), 2021 - 2033 (USD Million)
Fig. 21 Asia Pacific Onasemnogene abeparvovec (Zolgensma), 2021 - 2033 (USD Million)
Fig. 22 Latin America Onasemnogene abeparvovec (Zolgensma), 2021 - 2033 (USD Million)
Fig. 23 MEA Onasemnogene abeparvovec (Zolgensma), 2021 - 2033 (USD Million)
Fig. 24 Company categorization
Fig. 25 Company market position analysis
Fig. 26 Strategic framework

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.